ONCOLYTICS BIOTECH INC — Form 8-K
Filed July 13, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
Oncolytics reported clinical progress on REO 033, a randomized Phase 2 trial of pelareorep plus FOLFIRI/bevacizumab for RAS-mutant MSS colorectal cancer. Approximately half of planned clinical sites activated by end of July 2026 with 20+ patients pre-identified; remaining sites expected activated by end of August. Company scheduled Type D meeting with FDA in first half of August 2026 to discuss adding Part B—a registration-directed study component designed to support accelerated and full approval—with Part A tumor response data expected by year-end 2026 and Part B enrollment targeted for Q1 2027.
Why this rating
Meaningful regulatory progress (FDA Type D meeting, Fast Track designation) and active trial enrollment for mid-stage biotech. Relative to $72M market cap, advancement of lead asset toward registration pathway is significant; however, no Phase 3 initiation confirmed yet.
See more from July 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.